SKYE Skye Bioscience, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1516551 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY26.5%
TTM EPS YoY126.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-220.3%
ROA-162.4%
ROIC (approx.)-557.6%
Asset turnover—
Leverage & solvency
Liabilities / assets73.2%
Debt / equity0.00x
Current ratio1.36x
Interest coverage-4,388.42x
Cash quality & payout
Operating cash flow / net income0.81x
Accruals ratio-30.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $42.36M | $18.70M | $5.82M | $6.01M | $2.93M |
| SG&A expense | $15.80M | $17.73M | $7.85M | $6.09M | $4.92M |
| Operating income | -$58.16M | -$30.19M | -$34.74M | -$18.31M | -$7.85M |
| Interest expense | $0 | $749,308 | $906,270 | $665,133 | $769,159 |
| Pretax income | -$55.92M | -$26.56M | -$37.64M | -$19.47M | -$8.52M |
| Income tax | $5,400 | $10,071 | $3,600 | $6,741 | $2,100 |
| Net income | -$55.92M | -$26.57M | -$37.64M | -$19.48M | -$8.52M |
| EBITDA | -$57.44M | -$29.89M | -$34.61M | -$18.20M | -$7.81M |
| EPS (basic) | -1.41 | -0.73 | -5.37 | -8.77 | -0.02 |
| EPS (diluted) | -1.41 | -0.73 | -5.37 | -8.77 | -0.02 |
| Weighted avg. shares (diluted) | 39.66M | 36.49M | 7.01M | 2.22M | 406.60M |
| Balance sheet | |||||
| Cash & equivalents | $5.88M | $68.42M | $10.34M | $1.25M | $8.99M |
| Short-term investments | $19.85M | $0 | — | — | — |
| Current assets | $27.09M | $70.83M | $11.65M | $8.94M | $9.61M |
| PP&E, net | $898,930 | $1.43M | $43,276 | $87,854 | $87,710 |
| Total assets | $28.31M | $72.76M | $11.94M | $9.11M | $9.86M |
| Current liabilities | $8.21M | $4.34M | $13.90M | $12.12M | $3.91M |
| Total liabilities | $8.29M | $4.61M | $14.07M | $12.12M | $3.99M |
| Shareholders' equity | $20.02M | $68.15M | -$2.13M | -$3.01M | $5.86M |
| Shares outstanding | 4.17M | 30.97M | 12.35M | 3.65M | 476.11M |
| Cash flow statement | |||||
| Operating cash flow | -$43.06M | -$25.24M | -$13.95M | -$12.74M | -$6.47M |
| Capital expenditure | $6,312 | $1.60M | $12,550 | $28,060 | $90,866 |
| Free cash flow | -$43.07M | -$26.84M | -$13.96M | -$12.77M | -$6.57M |
| Investing cash flow | -$19.50M | -$245,615 | $6.60M | $5.21M | -$90,866 |
| Financing cash flow | $29,571 | $83.56M | $16.44M | -$208,794 | $13.08M |
| Depreciation & amortization | $723,352 | $298,640 | $124,251 | $114,998 | $34,131 |
| Stock-based compensation | $7.77M | $8.32M | $987,510 | $629,032 | $869,206 |
Free plan shows the latest 5 periods; Pro shows all 15 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-19 06:28.